Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Other Accumulated Expenses (2024 - 2026)

Maze Therapeutics' Other Accumulated Expenses history spans 3 years, with the latest figure at $5.0 million for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $5.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.0 million, a N/A change, with the full-year FY2025 number at $4.3 million, up 46.73% from a year prior.
  • Other Accumulated Expenses hit $5.0 million in Q1 2026 for Maze Therapeutics, up from $4.3 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for MAZE hit a ceiling of $5.1 million in Q3 2025 and a floor of $2.9 million in Q4 2024.
  • Historically, Other Accumulated Expenses has averaged $4.5 million across 3 years, with a median of $4.9 million in 2025.
  • The widest YoY moves for Other Accumulated Expenses: up 46.73% in 2025, down 46.73% in 2025.
  • Tracing MAZE's Other Accumulated Expenses over 3 years: stood at $2.9 million in 2024, then surged by 46.73% to $4.3 million in 2025, then increased by 17.14% to $5.0 million in 2026.
  • Business Quant data shows Other Accumulated Expenses for MAZE at $5.0 million in Q1 2026, $4.3 million in Q4 2025, and $5.1 million in Q3 2025.